Tag: Europe
-
University Spins Off Biomarker Targeting Company
The University of Liège in Belgium announced the first spin-off company, called Targetome, from GIGA, the university’s applied geno-proteomics center. The company is led by Vincent Castronovo (pictured left), a university faculty member on whose research the company is based. The company is developing a new technique to identify biomarkers which are over-expressed in certain…
-
Report: U.S. Scientific Dominance Slipping
A study from Thomson Reuters, Global Research Report: United States, released today (12 November), found that research output from the United States has been surpassed by that of Asia and Europe. The report is based on an analysis of research papers in the most influential journals, as indexed by Thomson Reuters in the Web of…
-
Institutions, Companies Form Psychiatric Trial Database
An international academic-industry collaboration brings together data on 23,401 anonymous patients from 67 trials on 11 compounds in over 25 countries, to form the largest database of clinical trial data ever created in psychiatric research. The project known as NEWMEDS — Novel Methods leading to NeW MEdications in Depression and Schizophrenia — is led by…
-
European Venture Deals Decline, Euro Volume Up
Dow Jones VentureSource reports that venture capitalists put €916 million ($1.3 billion) into 198 deals for European companies in the third quarter in 2010, the lowest quarterly deal count for Europe since Dow Jones VentureSource began tracking the region ten years ago. Investment volume rose 6 percent from €866 million, despite the 25 percent drop…
-
Global R&D Spending Among Innovators Declines in 2009
Total R&D spending among the world’s top spenders on innovation dropped in 2009 for the first time in the 13 years studied, according to the annual survey by management consulting firm Booz & Company. At the same time, most science-related companies, especially those in the health care industry, increased their R&D spending, with the pharmaceutical…
-
Europe R&D Network Approves 2011 Funding Targets
EUREKA, an intergovernmental consortium of European and neighboring organizations focused on research and development, approved funding €51 million ($US 70.4 million) for 56 new projects next year. The projects were selected by EUREKA’s High Level Group Representatives and National Project Coordinators from 40 countries. The funded R&D projects covered the fields of electronics, IT and…
-
Worldwide Corporate R&D Drops, Pharma/Biotech Bucks Trend
The European Commission’s 2010 “EU Industrial R&D Investment Scoreboard” shows that R&D investment by the world’s top 1,400 companies dropped by nearly 2 percent in the companies’ 2009 fiscal years, but with pharmaceutical/biotech companies and companies in Asian countries increasing their R&D spending. The worldwide economic recession, the report indicates, is taking its toll on…
-
Life-Cycle Analysis Shows CFL Bulbs Most Enviro Friendly
Researchers from Empa, the Swiss Federal Laboratories for Materials Testing and Research in Duebendorf, studied the full lifetime of four lighting technologies, and found compact fluorescent lighting (CFL) to inflict the least environmental damage. The analysis includes consideration of CFL’s mercury content, since exposure to elemental mercury when absorbed through the lungs can cause neurological…
-
European Approval Given for Cancer Pain Drug
BioDelivery Sciences International (BDSI), a drug delivery technology company in Raleigh, North Carolina, said today its drug BREAKYL received approval for marketing by the German review authorities. Meda, a Swedish pharmaceutical company, partnered with BDSI on the development of the drug. The approval of BREAKYL by Germany will apply to all Europe Commission countries, since…
-
Max Planck Institute, GSK to Collaborate on Diabetes Drugs
The Max Planck Institute of Biochemistry (MPI) in Martinsried, Germany and the German subsidiary of pharmaceutical company GlaxoSmithKline (GSK) have agreed on a partnership to develop new drugs for the treatment of type 2 diabetes. Max Planck Innovation, MPI’s technology transfer organisation, says the agreement is worth several million euros and covers a three-year period.…